| Budget Amount *help |
¥33,400,000 (Direct Cost: ¥33,400,000)
Fiscal Year 2009: ¥6,700,000 (Direct Cost: ¥6,700,000)
Fiscal Year 2008: ¥6,700,000 (Direct Cost: ¥6,700,000)
Fiscal Year 2007: ¥6,700,000 (Direct Cost: ¥6,700,000)
Fiscal Year 2006: ¥6,800,000 (Direct Cost: ¥6,800,000)
Fiscal Year 2005: ¥6,500,000 (Direct Cost: ¥6,500,000)
|
|---|
| Research Abstract |
In many of human leukemias, we still do not have effective molecular targeted therapies nor accurate diagnostic means. To address these issues, here we have purified and collected CD133-positive stem cell fractions from bone marrow of affected individuals, and applied a variety of genomics approaches toward such purified fractions. Through such screenings, we could construct a prediction scheme for patients' prognosis based on the expression level of the selected genes, and could identify novel oncogenes responsible for the development of acute myeloid leukemia.
|
